Hayward, Calif., April. 30, 2018 — Predicine today announced a 600-gene liquid biopsy panel, PredicineATLAS, to help drug companies accelerate clinical trials and the development of targeted cancer drugs and immunotherapies. The panel is expected to be one of the industry’s largest liquid biopsy panels, covering gene content of major commercially available TMB panels in...

Predicine, a Hayward, Calif.-based precision medicine company, today announced it has completed its $13.5M Series A financing from Sangel Capital, Rongsheng Investment, and Highlight Capital. Predicine provides an integrated oncology biomarker solution that includes an innovative RNA+DNA liquid biopsy test and a one-stop biomarker and data analysis platform to support targeted cancer therapeutics and global clinical...